Abstract
Fatigue occurs in many patients with rheumatoid arthritis (RA) and other chronic inflammatory diseases and may be defined as an overwhelming sense of tiredness, lack of energy, and feeling of exhaustion. It can be restrictive and severely disabling. We recently found more than 3/4 of systemic lupus erythematosus patients to be significantly affected by this phenomenon. We hypothesized that fatigue in patients with RA might be comparable to sickness behavior in animals possibly caused by disturbances in interleukin-1 beta signaling pathways and thus accessible to blockade by biologic agents. This study compared measures of disease behavior and fatigue symptoms in eight RA patients before and at three time points during treatment with daily administration of anakinra.
References
Wolfe F, Hawley DJ, Wilson K (1996) The prevalence and meaning of fatigue in rheumatic diseases. J Rheumatol 23:1407–1417
Koike T, Kazuma K, Kawamura S (2000) The relationship between fatigue, coping behavior, and inflammation in patients with rheumatoid arthritis. Mod Rheumatol 10:141–149
Krupp LB, LaRocca NG, Muir J, Steinberg AD (1990) A study of fatigue in systemic lupus erythematosus. J Rheumatol 17:1450–1452
Tench CM, McCurdie I, White PD, D’Cruz DP (2000) The prevalence of fatigue in systemic lupus erythematosus. Rheumatology 39:1249–1254
Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G (2002) Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Rheumatol 29:482–486
Comi G, Leocani L, Rossi P, Colombo B (2001) Physiopathology and treatment of fatigue in multiple sclerosis. J Neurol 248:174–179
Kurzrock R (2001) The role of cytokines in cancer-related fatigue. Cancer [Suppl] 92:1684–1688
Krupp LB, Pollina DA (1996) Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol 9:456–460
Kelley KW, Hutchison K, French R et al (1997) Central interleukin-1 receptors as mediators of sickness. In: Moore PM, Lahita RG (eds) Neuropsychiatric manifestations of systemic lupus erythematosus. Ann N Y Acad Sci 823:234–246
Rinehart J, Hersh E, Issell B, Triozzi P, Buhles W, Neidhart J (1997) Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology Group Study 8940. Cancer Invest 15:403–410
Farrar WL, Killian PL, Ruff MR, Hill JM, Pert CB (1987) Visualization and characterization of interleukin-1 receptors in brain. Endocrinology 139:459–463
Konsman JP, Blond D, Vigues S (2000) Neurobiology of interleukin-1 receptors: getting the message. Eur Cytokine Netw 11:699–702
Carrié A, Jun L, Bienvenu T et al (1999) A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation. Nature Genetics 23:25–31
Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
http://www.das-score.nl/www.das-score.nl/DAS-frame-1.htm
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123
Bresnihan B (2001) The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Bio Drugs 15:87–97
Guyatt GH, Townsend M, Berman LB, Keller JL (1987) A comparison of Likert and visual analogue scales for measuring change in function. J Chron Dis 40:1129–1133
Wang B, Gladman DD, Urowitz MB (1998) Fatigue in lupus is not correlated with disease activity. J Rheumatol 25:892–895
Bruce IN, Mak VC, Hallett DC, Gladman DD, Urowitz MB (1999) Factors associated with fatigue in patients with systemic lupus erythematosus. Ann Rheum 58:379–381
Omdal R, Waterloo K, Koldingsnes W, Husby G, Mellgren SI (2003) Fatigue in patients with systemic lupus erythematosus: the psychosocial aspects. J Rheumatol 30:283–287
Schiller JH, Storer BE, Witt PL et al (1991) Biological and clinical effects of intravenous tumor necrosis factor-α administered three times weekly. Cancer Res 51:1651–1658
Layé S, Lundkvist J, Bartfai T (1999) Cytokines in the brain. In: Thèze J (ed) The cytokine network and immune functions. Oxford University Press, New York, pp 262–269
Greenberg DB, Gray JL, Mannix CM, Eisenthal S, Carey M (1993) Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage 8:196–200
Riemsa RP, Rasker JJ, Taal E, Griep EN, Wouters JMGW, Wiegman O (1998) Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support. Br J Rheumatol 37:1042–1046
Belza BL (1995) Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol 22:639–643
Giovannoni G, Thompson AJ, Miller DH, Thompson EJ (2001) Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology 57:676–681
Bakshi R, Miletich RS, Henschel K et al (1999) Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients. Neurology 53:1151–1153
Acknowledgement
The authors would like to thank Mrs. Monica Crossman Meling for linguistic help.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Omdal, R., Gunnarsson, R. The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis—a pilot study. Rheumatol Int 25, 481–484 (2005). https://doi.org/10.1007/s00296-004-0463-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-004-0463-z